ライフサイエンスコーパス: carboplatin

1 was associated with an improved response to carboplatin.

2 ine for one course, with optional periocular carboplatin.

3 y profile similar to that of the parent drug carboplatin.

4 and one patient had an allergic reaction to carboplatin.

5 R inhibitor as monotherapy and combined with carboplatin.

6 rates without additive effects observed for carboplatin.

7 CIB2 also sensitized ovarian cancer cells to carboplatin.

8 rs and sensitized chemoresistant OC cells to carboplatin.

9 ) polymerase (PARP) inhibitor, combined with carboplatin.

10 and combined with DNA-damaging drugs such as carboplatin.

11 espond to Pt(II) drugs such as cisplatin and carboplatin.

12 num-based chemotherapeutics, oxaliplatin and carboplatin.

13 th dose-dense weekly paclitaxel and 3-weekly carboplatin.

14 [66.7%]) was not increased further by adding carboplatin (17 of 26 [65.4%]).

15 ally higher with cisplatin (32.6%) than with carboplatin (18.7%).

16 Fluorinated carboplatin ((19)F-FCP) was synthesized using (19)F-labe

17 of intravenous pemetrexed (500 mg/m(2)) with carboplatin (5 mg/mL per min) or cisplatin (75 mg/m(2);

18 t triple therapy (e.g., melphalan 0.4 mg/kg, carboplatin 50 mg, and topotecan 2 mg) and noting certai

19 eceived his first of two cycles of high-dose carboplatin 700 mg/m(2) on days -5, -4, and -3 and etopo

20 al rates when carboplatin was added (without carboplatin, 73.5%; 95% CI, 64.1%-80.8% vs with carbopla

21 boplatin, 73.5%; 95% CI, 64.1%-80.8% vs with carboplatin, 85.3%; 95% CI, 77.0%-90.8%; hazard ratio, 0

22 the present pharmaceutical options, such as carboplatin a metallodrug based on Pt coordination chemi

23 Carboplatin added to cabazitaxel showed improved clinica

24 cess used in our trial showed that veliparib-carboplatin added to standard therapy resulted in higher

25 Following IVC (vincristine, etoposide, and carboplatin), adjuvant treatments included intraophthalm

26 ree survival as compared with paclitaxel and carboplatin administered every 3 weeks among patients re

27 he addition of bevacizumab to paclitaxel and carboplatin administered every 3 weeks has shown efficac

28 ) or nivolumab 5 or 10 mg/kg plus paclitaxel-carboplatin (all histologies).

29 ression-free survival versus paclitaxel plus carboplatin alone, with the greatest clinical benefit in

30 with a 5-drug combination of vincristine and carboplatin, alternating with cyclophosphamide, idarubic

31 ve courses of HDCT consisting of 700 mg/m(2) carboplatin and 750 mg/m(2) etoposide, each for 3 consec

32 efficacy of the addition of palifosfamide to carboplatin and etoposide in extensive stage (ES) small-

33 ncers preferentially survived treatment with carboplatin and etoposide in vitro and in human MCC xeno

34 (VEC) and group B patients were treated with carboplatin and etoposide, alternating with cyclophospha

35 Atezolizumab plus carboplatin and nab-paclitaxel could be a potential neoa

36 y of the PD-L1 inhibitor, atezolizumab, with carboplatin and nab-paclitaxel given as neoadjuvant trea

37 and after bevacizumab plus chemotherapy with carboplatin and nab-paclitaxel in advanced NSCLC patient

38 ter randomized phase II neoadjuvant trial of carboplatin and nanoparticle albumin-bound paclitaxel (C

39 The pCR rates between the carboplatin and noncarboplatin arms were compared.

40 Cisplatin and its platinum analogs, carboplatin and oxaliplatin, are some of the most widely

41 Carboplatin and paclitaxel administered every 3 weeks is

42 oved progression-free survival when added to carboplatin and paclitaxel as first-line therapy in adva

43 We evaluated linifanib with carboplatin and paclitaxel as first-line therapy of adva

44 If patients discontinued carboplatin and paclitaxel before progression, they coul

45 Trebananib plus carboplatin and paclitaxel did not improve progression-f

46 The combination of trebananib plus carboplatin and paclitaxel did not produce new safety si

47 lts show that trebananib in combination with carboplatin and paclitaxel is minimally effective in thi

48 The combination of MSU-42011 and carboplatin and paclitaxel reduced macrophages in the lu

49 paclitaxel, and continued as monotherapy if carboplatin and paclitaxel were discontinued before prog

50 nts receiving adjuvant first-line therapy of carboplatin and paclitaxel with curative intent.

51 patients received concurrent chemotherapy of carboplatin and paclitaxel with or without cetuximab, an

52 ve to eight cycles of chemotherapy involving carboplatin and paclitaxel, and an Eastern Cooperative O

53 veliparib versus placebo in combination with carboplatin and paclitaxel, and continued as monotherapy

54 trexed maintenance therapy or to 4 cycles of carboplatin and pemetrexed alone followed by indefinite

55 ed the effects of the chemotherapeutic drugs carboplatin and PX-866 to reduce proliferation and survi

56 ine mutations benefited from the addition of carboplatin and those with BRCA1 and BRCA2 mutations sho

57 rian cancer models treated repetitively with carboplatin and validated in human specimens.

58 owed by three alternating administrations of carboplatin and vincristine for two courses and topoteca

59 were randomly assigned to receive veliparib-carboplatin, and 44 patients were concurrently assigned

60 clusion Topotecan combined with vincristine, carboplatin, and aggressive focal therapies is an effect

61 ximab vedotin (BV) and augmented ifosfamide, carboplatin, and etoposide (augICE), we assessed clinica

62 b vedotin, followed by augmented ifosfamide, carboplatin, and etoposide (ICE).

63 ycles of adjuvant chemotherapy (vincristine, carboplatin, and etoposide).

64 nib) or chemotherapy (rituximab, ifosfamide, carboplatin, and etoposide).

65 plus cisplatin, 18 received pemetrexed plus carboplatin, and four received a combination.

66 Preoperative combination of gemcitabine, carboplatin, and iniparib is active in the treatment of

67 isplatin, nivolumab 10 mg/kg plus paclitaxel-carboplatin, and nivolumab 5 mg/kg plus paclitaxel-carbo

68 platinum-based anticancer agents cisplatin, carboplatin, and oxaliplatin represent a spectacular tra

69 Platinum-based drugs (cisplatin, carboplatin, and oxaliplatin) are widely used therapeuti

70 The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment o

71 Combination of pembrolizumab, carboplatin, and pemetrexed could be an effective and to

72 toxicity assessment, RR in cisplatin versus carboplatin, and RR in molecularly defined subgroups, in

73 taxel, and trastuzumab (ACTH) and docetaxel, carboplatin, and trastuzumab (TCH).

74 etaxel and cyclophosphamide (TC); docetaxel, carboplatin, and trastuzumab (TCH); or doxorubicin and c

75 concurrently with trastuzumab or docetaxel, carboplatin, and trastuzumab for six cycles are recommen

76 ose, 420 mg maintenance doses) or docetaxel, carboplatin, and trastuzumab plus pertuzumab (docetaxel

77 ansine plus pertuzumab (n=223) or docetaxel, carboplatin, and trastuzumab plus pertuzumab (n=221).

78 23 (55.7%) of 221 patients in the docetaxel, carboplatin, and trastuzumab plus pertuzumab group (abso

79 n grade 3-4 adverse events in the docetaxel, carboplatin, and trastuzumab plus pertuzumab group were

80 plus dual HER2-targeted blockade (docetaxel, carboplatin, and trastuzumab plus pertuzumab) resulted i

81 3 patients vs 11 [5%] of 219 with docetaxel, carboplatin, and trastuzumab plus pertuzumab), fatigue (

82 compared with patients receiving docetaxel, carboplatin, and trastuzumab plus pertuzumab, fewer pati

83 umab emtansine plus pertuzumab or docetaxel, carboplatin, and trastuzumab plus pertuzumab.

84 so exhibited enhanced ABCB5 positivity after carboplatin- and etoposide-based chemotherapy, pointing

85 Carboplatin- and etoposide-resistant MCC cell lines exhi

86 Although cisplatin and carboplatin are used primarily in germ cell, breast and

87 ally per day plus pemetrexed 500 mg/m(2) and carboplatin area under curve 5 intravenously every 3 wee

88 tem to 4 cycles of pembrolizumab 200 mg plus carboplatin area under curve 5 mg/mL per min and pemetre

89 zumab plus pertuzumab (docetaxel 75 mg/m(2); carboplatin area under the concentration-time curve 6 mg

90 1 receptor antagonist for adults who receive carboplatin area under the curve >/= 4 mg/mL per minute

91 us cabazitaxel 20-25 mg/m(2) and intravenous carboplatin area under the curve (AUC) 3-4 mg/mL per min

92 h cycle with investigator's choice of either carboplatin area under the curve 5-6 mg/mL per min or ci

93 h cycle with investigator's choice of either carboplatin area under the curve 5-6 mg/mL/min or cispla

94 eeks or paclitaxel 175 mg/m(2) combined with carboplatin area under the curve 6 every 3 weeks) until

95 ; dacarbazine 1,000 mg/m(2) every 3 weeks or carboplatin area under the curve 6 plus paclitaxel 175 m

96 latin 50 mg/m(2) and four adjuvant cycles of carboplatin area under the curve [AUC] 5 and paclitaxel

97 y using minimisation to group 1 (intravenous carboplatin area under the curve [AUC]5 or AUC6 and 175

98 an cancer were randomly assigned to group 1 (carboplatin area under the curve [AUC]5 or AUC6 and 175

99 before chemotherapy (cisplatin 80 mg/m(2) or carboplatin area under the curve of 5 on day 1 plus etop

100 es, and were randomly assigned to concurrent carboplatin (area under curve 6) once every 3 weeks for

101 ith intravenous paclitaxel (200 mg/m(2)) and carboplatin (area under curve 6; 6 mg/mL per min) plus n

102 mg/m(2) intravenously [IV] on days 1 and 8), carboplatin (area under curve of 2 IV on days 1 and 8),

103 ocks within strata (block size of 3 or 6) to carboplatin (area under the concentration curve 6 mg/mL

104 cycles of bevacizumab (15 mg/kg, day 1) plus carboplatin (area under the concentration curve [AUC] 4,

105 ed 1:1:1 to six 21-day cycles of intravenous carboplatin (area under the concentration v time curve 6

106 ous gemcitabine 1000 mg/m(2) and intravenous carboplatin (area under the concentration-time curve 2 m

107 axel (100 mg/m(2)) on days 1, 8, and 15, and carboplatin (area under the curve 5; 5 mg/mL per min) on

108 therapy was either cisplatin (70 mg/m(2)) or carboplatin (area under the curve [AUC]4.5/AUC5, for glo

109 omly assigned (1:1:1) to receive intravenous carboplatin (area under the curve [AUC]5 or AUC6) and in

110 e randomly assigned to 12 wk of preoperative carboplatin (area under the curve of 2, weekly) and nab-

111 on days 1 and 8 of each cycle), plus either carboplatin (area under the curve of 4.5 mg/mL per min a

112 paclitaxel (200 mg/m(2); every 21 days) plus carboplatin (area under the curve of 6 by modified Calve

113 ients and Methods Patients were treated with carboplatin (area under the curve, 5 mg/mLmin) combined

114 FU 1,000 mg/m(2) (days 1-4) every 21 days or carboplatin (area under the curve, 5; day 1) plus paclit

115 e six cycles of paclitaxel (175 mg/m(2)) and carboplatin (area under the serum concentration-time cur

116 taxel [175 mg/m(2) of body surface area] and carboplatin [area under the curve 5]) or the same chemot

117 ravenously every 3 weeks) plus chemotherapy (carboplatin [area under the curve 6 mg/mL per min every

118 RCA1 and BRCA2 mutations achieved pCR in the carboplatin arm vs 44 of the 121 patients (36.4%) in the

119 a and thrombocytopenia were more common with carboplatin, as were hypertension, infection, thromboemb

120 andomly assigned in a 1:1 fashion to receive carboplatin at area under the serum concentration-time c

121 per day on days 1 to 3 every 21 days (CE) or carboplatin at area under the serum concentration-time c

122 t cell lines and compared with cisplatin and carboplatin at different concentrations.

123 taxel 25 mg/m(2) with or without intravenous carboplatin AUC 4 mg/mL per min.

124 nfusion over 24 h, days 1 and 2; one dose of carboplatin AUC 5, day 3; three doses of etoposide 200 m

125 based chemotherapy ([cisplatin 75 mg/m(2) or carboplatin AUC 5-6 plus pemetrexed 500 mg/m(2)] every 3

126 Eligible patients received carboplatin AUC of 5 plus paclitaxel 175 mg/m(2) by infu

127 f bevacizumab (10 mg/kg, days 1 and 15) plus carboplatin (AUC 5, day 1) plus pegylated liposomal doxo

128 n consisting of paclitaxel (200 mg/m(2)) and carboplatin (AUC 6).

129 ly at a dose of 80 mg per square meter, plus carboplatin (AUC, 6) for six cycles.

130 otherapy (six 3-weekly cycles of intravenous carboplatin [AUC 5 or 6] and paclitaxel 175 mg/m(2) of b

131 d 80 mg/m(2) paclitaxel weekly), or group 3 (carboplatin AUC2 and 80 mg/m(2) paclitaxel weekly).

132 d 80 mg/m(2) paclitaxel weekly), or group 3 (carboplatin AUC2 weekly and 80 mg/m(2) paclitaxel weekly

133 (group 2); or intravenous dose-fractionated carboplatin (AUC2) and intravenous dose-fractionated pac

134 ing radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m(2) given intrav

135 ravenous paclitaxel every 3 weeks), group 2 (carboplatin AUC5 or AUC6 every 3 weeks and 80 mg/m(2) pa

136 mg/m(2) paclitaxel every 3 weeks), group 2 (carboplatin AUC5 or AUC6 every 3 weeks and 80 mg/m(2) pa

137 Each 3-week cycle consisted of carboplatin AUC5 or AUC6 plus paclitaxel 175 mg/m(2), or

138 ombination therapy was M6620 90 mg/m(2) with carboplatin AUC5.

139 cycle (control group; group 1); intravenous carboplatin (AUC5 or AUC6) on day 1 and intravenous dose

140 Addition of carboplatin, B, or both increased conversion rates.

141 ent allocation on the basis of CGA (CGA arm: carboplatin-based doublet for fit patients, docetaxel fo

142 on on the basis of PS and age (standard arm: carboplatin-based doublet if PS </= 1 and age </= 75 yea

143 arms, 35.1% and 45.7% of patients received a carboplatin-based doublet, 64.9% and 31.3% received doce

144 is therapy sensitized breast cancer cells to carboplatin-based therapy and increased host survival.

145 rom 185 patients who relapsed after adjuvant carboplatin between January 1987 and August 2013 at 31 c

146 eased the sensitivity of cancer cells toward carboplatin both in vitro and in vivo.

147 He was briefly treated with gemcitabine and carboplatin, but this was discontinued as a result of ra

148 irinapant sensitizes CA125-negative cells to carboplatin by mediating degradation of cIAP causing cle

149 lls treated with doxorubicin, paclitaxel, or carboplatin by suppressing apoptosis and upregulating NF

150 rular filtration rate (GFR) is essential for carboplatin chemotherapy dosing; however, the best metho

151 ty data for trilaciclib plus gemcitabine and carboplatin chemotherapy in patients with metastatic tri

152 Adding pemetrexed and carboplatin chemotherapy to an oral tyrosine kinase inhi

153 Adding pemetrexed and carboplatin chemotherapy to gefitinib significantly prol

154 f combining trilaciclib with gemcitabine and carboplatin chemotherapy.

155 and its expression increases in response to carboplatin chemotherapy.

156 are deadly malignancies that relapse despite carboplatin chemotherapy.

157 t to chemotherapeutic agents (5-fluoruracil, carboplatin, cisplatin, eribulin, and paclitaxel), based

158 ablished CSC-potent agent, and cisplatin and carboplatin, clinically used platinum drugs.

159 us paclitaxel 175 mg/m(2), or an alternative carboplatin combination regimen, or carboplatin monother

160 toposide, and melphalan regimen consisted of carboplatin continuous infusion of area under the plasma

161 in this setting is unlikely, but the role of carboplatin could be evaluated in definitive studies, id

162 ed a multidrug induction regimen (cisplatin, carboplatin, cyclophosphamide, vincristine, and etoposid

163 py (paclitaxel plus carboplatin, paclitaxel, carboplatin, dacarbazine, or oral temozolomide).

164 Results AZD1775 plus carboplatin demonstrated manageable toxicity; fatigue (8

165 olerated dose of AZD1775 in combination with carboplatin demonstrated target engagement.

166 mcitabine plus cisplatin or gemcitabine plus carboplatin, depending on cisplatin eligibility) adminis

167 rting on the development of an (18)F-labeled carboplatin derivative ((18)F-FCP) that has the potentia

168 This strategy of using a new therapeutic carboplatin derivative to quantify and track platinum dr

169 In the MC38 model, paclitaxel/carboplatin did not result in an appreciable change in s

170 show that oxaliplatin, unlike cisplatin and carboplatin, does not kill cells through the DNA-damage

171 odel reduced the fraction of patients with a carboplatin dose absolute percentage error > 20% to 14.1

172 ter of body-surface area every 3 weeks, plus carboplatin (dose equivalent to an area under the curve

173 We performed a comparison of carboplatin dosing accuracy on the basis of an absolute

174 rapy-induced overactivation, mice were given carboplatin, doxorubicin, or cyclophosphamide and were c

175 oviding clinical proof that AZD1775 enhances carboplatin efficacy in TP53-mutated tumors.

176 sulfan and melphalan and at least 72 h after carboplatin etoposide, and melphalan.

177 rednisolone, and her cancer was treated with carboplatin, etoposide and radiotherapy.

178 ne) followed by 3 cycles of ICE (ifosfamide, carboplatin, etoposide).

179 signed (1:1) to busulfan and melphalan or to carboplatin, etoposide, and melphalan by minimisation, b

180 an and melphalan group and 188 of 302 in the carboplatin, etoposide, and melphalan group had an event

181 e busulfan and melphalan group and 11 in the carboplatin, etoposide, and melphalan group had died wit

182 d melphalan group vs 103 [38%] of 270 in the carboplatin, etoposide, and melphalan group), infection

183 clusive disease versus 21 (9%) of 239 in the carboplatin, etoposide, and melphalan group.

184 The carboplatin, etoposide, and melphalan regimen consisted

185 ed: 296 to busulfan and melphalan and 302 to carboplatin, etoposide, and melphalan.

186 lfan and melphalan and 29 (10%) who received carboplatin, etoposide, and melphalan.

187 caused fewer severe adverse events than did carboplatin, etoposide, and melphalan.

188 py with busulfan and melphalan compared with carboplatin, etoposide, and melphalan.

189 pa/cyclophosphamide followed by dose-reduced carboplatin/etoposide/melphalan (n = 176) or single tran

190 elphalan (n = 176) or single transplant with carboplatin/etoposide/melphalan (n = 179).

191 n a greater frequency of drug delivery) plus carboplatin every 3 weeks or the addition of bevacizumab

192 to six cycles of etoposide plus cisplatin or carboplatin every 3 weeks, until disease progression or

193 Carboplatin exposure was not associated with HAD.

194 Olaparib plus paclitaxel and carboplatin followed by maintenance monotherapy signific

195 ommonly treated with adjuvant doxorubicin or carboplatin following amputation of the affected limb.

196 ents who experience a relapse after adjuvant carboplatin for clinical stage I seminoma can be success

197 umab combined with carboplatin-paclitaxel or carboplatin-gemcitabine) or the most active non-bevacizu

198 p) and 337 were randomly assigned to receive carboplatin-gemcitabine-bevacizumab (standard group).

199 e considered to be related to paclitaxel and carboplatin (general physical health deterioration and p

200 y interval [PI], 36 to 66%) in the veliparib-carboplatin group versus 26% (95% PI, 9 to 43%) in the c

201 ly for the nivolumab 5 mg/kg plus paclitaxel-carboplatin group, with a 2-year OS rate of 62%.

202 to triple-negative breast cancer, veliparib-carboplatin had an 88% predicted probability of success

203 apy with vincristine sulfate, etoposide, and carboplatin had failed in 10 patients (91%) and 6 eyes (

204 iniparib in combination with gemcitabine and carboplatin in early-stage triple-negative and BRCA1/2 m

205 points with trilaciclib plus gemcitabine and carboplatin in patients with metastatic triple-negative

206 In contrast, carboplatin increased response rates in patients without

207 Purpose Adjuvant carboplatin is one of three management strategies that m

208 dered related to trebananib, paclitaxel, and carboplatin (lung infection and neutropenic colitis); tw

209 The best carboplatin model utilized canine lines for gene identif

210 ernative carboplatin combination regimen, or carboplatin monotherapy.

211 line therapy) received cisplatin (n = 43) or carboplatin (n = 43).

212 ed to cabazitaxel (n=79) or cabazitaxel plus carboplatin (n=81) in phase 2.

213 Additional options are atezolizumab/carboplatin/nab-paclitaxel, atezolizumab/carboplatin/pac

214 atin/paclitaxel/bevacizumab, or atezolizumab/carboplatin/nab-paclitaxel.

215 n combination with the standard-of-care drug carboplatin, ND-646 markedly suppressed lung tumor growt

216 erated dose of cabazitaxel of 25 mg/m(2) and carboplatin of AUC 4 mg/mL per min was selected for phas

217 n days 1 and 8 (group 2), or gemcitabine and carboplatin on days 2 and 9 plus trilaciclib on days 1,

218 chemotherapy with 45 mg/m(2) paclitaxel and carboplatin once a week (AUC 2); 2 weeks after chemoradi

219 In stage II to III TNBC, addition of either carboplatin or bevacizumab to NACT increased pCR rates,

220 Patients assigned to either carboplatin or bevacizumab were less likely to complete

221 SC enrichment, in response to treatment with carboplatin or doxorubicin.

222 -paclitaxel; paclitaxel; or gemcitabine plus carboplatin) or placebo plus chemotherapy.

223 tigator-choice chemotherapy (paclitaxel plus carboplatin, paclitaxel, carboplatin, dacarbazine, or or

224 sponse rates between cisplatin-etoposide and carboplatin-paclitaxel (58% vs 56%; P = .26), respective

225 nd 172 were assigned to receive placebo plus carboplatin-paclitaxel (control group).

226 tion with either etoposide-cisplatin (EP) or carboplatin-paclitaxel (CP).

227 4 hematological toxic effects compared with carboplatin-paclitaxel (eg, neutropenia [54% vs 23%; P <

228 ents were assigned to receive veliparib plus carboplatin-paclitaxel (veliparib group) and 172 were as

229 at the end of the second week of first cycle carboplatin-paclitaxel and bevacizumab (CPB) treatment.

230 IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide.

231 .0 Gy), and 3728 patients from 48 studies in carboplatin-paclitaxel groups (median age, 63 years; 65%

232 oxic effects between cisplatin-etoposide and carboplatin-paclitaxel in patients with non-small-cell l

233 combinations (eg, bevacizumab combined with carboplatin-paclitaxel or carboplatin-gemcitabine) or th

234 III disease receiving radiotherapy (RT) with carboplatin-paclitaxel or cisplatin-etoposide were ident

235 The toxic effect profiles favored the carboplatin-paclitaxel regimen.

236 Cisplatin-etoposide and carboplatin-paclitaxel regimens were associated with com

237 Concurrent chemotherapy (carboplatin-paclitaxel) and passively scattered PBT (74-

238 For cisplatin-etoposide vs carboplatin-paclitaxel, there was no significant differe

239 rom 151 consecutive EC patients treated with carboplatin/paclitaxel and 41.4Gy between 2009 and 2018.

240 s 60-Gy RT with concurrent and consolidation carboplatin/paclitaxel with or without cetuximab.

241 All patients were treated with nCRT (carboplatin/paclitaxel/41.4 Gy) followed by esophagectom

242 lizumab/carboplatin/pemetrexed, atezolizumab/carboplatin/paclitaxel/bevacizumab, or atezolizumab/carb

243 mab/carboplatin/nab-paclitaxel, atezolizumab/carboplatin/paclitaxel/bevacizumab, platinum-based two-d

244 ), the Expert Panel recommends pembrolizumab/carboplatin/(paclitaxel or nab-paclitaxel) or chemothera

245 additional treatment option is pembrolizumab/carboplatin/(paclitaxel or nab-paclitaxel).

246 on-study chemotherapy (taxane or gemcitabine-carboplatin), PD-L1 expression at baseline (combined pos

247 andard bevacizumab-containing regimen versus carboplatin-pegylated liposomal doxorubicin combined wit

248 Carboplatin-pegylated liposomal doxorubicin-bevacizumab

249 f whom 345 were randomly assigned to receive carboplatin-pegylated liposomal doxorubicin-bevacizumab

250 or the most active non-bevacizumab regimen: carboplatin-pegylated liposomal doxorubicin.

251 onal treatment options include pembrolizumab/carboplatin/pemetrexed, atezolizumab/carboplatin/paclita

252 1, the Expert Panel recommends pembrolizumab/carboplatin/pemetrexed.

253 nation of pemetrexed and either cisplatin or carboplatin (platinum-based chemotherapy) (74% vs 45%, r

254 tion with etoposide plus either cisplatin or carboplatin (platinum-etoposide) in treatment-naive pati

255 umab plus etoposide with either cisplatin or carboplatin (platinum-etoposide) showed a significant im

256 in plus pemetrexed for nonsquamous NSCLC and carboplatin plus gemcitabine for squamous histology.

257 ) on days 1 and 8 (group 1), gemcitabine and carboplatin plus intravenous trilaciclib 240 mg/m(2) on

258 ival with atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) versus the standard-o

259 rt the efficacy of ABCP or atezolizumab plus carboplatin plus paclitaxel (ACP) versus BCP in key pati

260 versus the standard-of-care bevacizumab plus carboplatin plus paclitaxel (BCP) in chemotherapy-naive

261 ths (95% CI, 12.7 months to not reached) for carboplatin plus paclitaxel (hazard ratio, 2.00; 95% CI,

262 modified Calvert formula; every 21 days) or carboplatin plus paclitaxel and bevacizumab (15 mg/kg; e

263 isplatin plus FU arm (62%) compared with the carboplatin plus paclitaxel arm (36%; P = .016).

264 /QALY, and first-line NIVO + IPI followed by carboplatin plus paclitaxel chemotherapy produced an inc

265 ally fit patients received concurrent weekly carboplatin plus paclitaxel followed by 3 cycles of cons

266 with PS 0 to 1 (bevacizumab may be added to carboplatin plus paclitaxel if no contraindications); co

267 a trend toward longer survival suggest that carboplatin plus paclitaxel should be considered as a ne

268 ods Patients were randomly assigned to nCRT (carboplatin plus paclitaxel with concurrent 41.4-Gy radi

269 s FU versus 59% (95% CI, 42.1% to 74.4%) for carboplatin plus paclitaxel.

270 h 8.1 months (95% CI, 6.6 to 8.8 months) for carboplatin plus paclitaxel.

271 assigned: 46 to cisplatin plus FU and 45 to carboplatin plus paclitaxel.

272 Chemotherapy was determined by histology: carboplatin plus pemetrexed for nonsquamous NSCLC and ca

273 Veliparib-carboplatin plus standard therapy was considered for HER

274 atinum-resistant ovarian cancer who received carboplatin plus the DNA methyltransferase inhibitor gua

275 sion and chemosensitivity to paclitaxel plus carboplatin (PTX/CBP) regimen, an effective neoadjuvant

276 umor (DAWT) and whether a regimen containing carboplatin (regimen UH1) in addition to regimen I agent

277 nduce immunogenic cell death, and paclitaxel/carboplatin, reported to cause immunogenically silent tu

278 ain a CA125-negative population enriched for carboplatin-resistant cancer initiating cells.

279 er kilogram of body weight of paclitaxel and carboplatin, respectively (P < .001 for each agent).

280 th the emergence of docetaxel resistance and carboplatin responsiveness in TNBC/BRCA1-mutated tumors.

281 ur results demonstrated that (19)F-FCP, like carboplatin, retains antitumor activity in various cell

282 chemotherapy with 175 mg/m(2) paclitaxel and carboplatin (target area under the curve of 6) given 21

283 antly longer treatment-response durations to carboplatin than did men without defects in genes encodi

284 DT and the standard-of-care chemotherapeutic carboplatin that evolved over time.

285 icantly increased the anti-tumor efficacy of carboplatin, the chemotherapy most commonly used to trea

286 to assess response to combination docetaxel/carboplatin therapy in a co-clinical trial involving tri

287 assess response to combination docetaxel and carboplatin therapy in a co-clinical trial involving tri

288 ce to docetaxel and increased sensitivity to carboplatin, therefore sequential docetaxel/carboplatin

289 ed evidence that the addition of neoadjuvant carboplatin to a regimen consisting of anthracycline, ta

290 We aimed to determine whether adding carboplatin to cabazitaxel would improve the outcomes of

291 carboplatin, therefore sequential docetaxel/carboplatin treatment could improve survival in TNBC/BRC

292 ecurrent ovarian carcinomas after paclitaxel/carboplatin treatment have higher levels of spleen tyros

293 ere treated with vincristine, etoposide, and carboplatin (VEC) and group B patients were treated with

294 leted treatment with multiagent chemotherapy-carboplatin, vincristine, temozolomide, procarbazine, lo

295 ed elevated disease-free survival rates when carboplatin was added (without carboplatin, 73.5%; 95% C

296 The toxicity of veliparib-carboplatin was greater than that of the control.

297 The distribution of cisplatin and carboplatin was mapped in additional 3D tumor mimics.

298 latin, and nivolumab 5 mg/kg plus paclitaxel-carboplatin were 33%, 47%, 47%, and 43%, respectively; 2

299 Twenty-three patients received M6620 with carboplatin, with mechanism-based hematologic toxicities

300 ine whether dose-dense weekly paclitaxel and carboplatin would prolong progression-free survival as c